Neuropathic pain

Current Opinion in Neurology

Volumn 14, Issue 5, 2001, Pages 641-647

  Koltzenburg, Martin ^a,b   Scadding, John ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CAPSAICIN; CARBAMAZEPINE; DEXTROMETHORPHAN; GABAPENTIN; LIDOCAINE; MEMANTINE; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; OPIATE; PHENYTOIN; PREDNISONE; SUBSTANCE P ANTAGONIST; THIOCTIC ACID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL MODEL; CLINICAL FEATURE; HYPERALGESIA; NERVE DEGENERATION; NERVE FIBER TRANSECTION; NERVE INJURY; NEUROPATHY; NONMYELINATED NERVE; PAIN; PERIPHERAL NERVE INJURY; REVIEW; SCHWANN CELL; SENSORY NERVE CELL;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COMPLEX REGIONAL PAIN SYNDROMES; HUMANS; NEURALGIA;

EID: 0034793749     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200110000-00014     Document Type: Review

References (65)

1. Neuronal plasticity: Increasing the gain in pain
2. Neuropathic pain: Aetiology, symptoms, mechanisms, and management
3. The molecular dynamics of pain control
4. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons
5. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
6. Subclinical sensory neuropathy in late-onset restless legs syndrome
7. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat
8. The role of neighboring intact dorsal root ganglion neurons in a rat neuropathic pain model
9. Change in mRNAs for neuropeptides and the GABA(A) receptor in dorsal root ganglion neurons in a rat experimental neuropathic pain model
10. VR1 protein expression increases in undamaged DRG neurons after partial nerve injury
11. Impaired nociception and pain sensation in mice lacking the capsaicin receptor
12. The properties of unmyelinated afferents change in a chronic constriction neuropathy
13. Uninjured C-fiber nociceptors develop spontaneous activity and alpha-adrenergic sensitivity following L6 spinal nerve ligation in monkey
14. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers
15. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury
16. Spared nerve injury: An animal model of persistent peripheral neuropathic pain
17. Dorsal root section elicits signs of neuropathic pain rather than reversing them in rats with L5 spinal nerve injury
18. Mechanical hyperalgesia after an L5 spinal nerve lesion in the rat is not dependent on input from injured nerve fibers
19. Axotomized and intact muscle afferents but no skin afferents develop ongoing discharges of dorsal root ganglion origin after peripheral nerve lesion
20. Potent analgesic effects of GDNF in neuropathic pain states
21. Sympathetic-sensory coupling after L5 spinal nerve lesion in the rat and its relation to changes in dorsal root ganglion blood flow
22. Tactile allodynia in the absence of C-fiber activation: Altered firing properties of DRG neurons following spinal nerve injury
23. Spinal nerve injury enhances subthreshold membrane potential oscillations in DRG neurons: Relation to neuropathic pain
24. Downregulation of tetrodotoxin-resistant sodium currents and upregulation of a rapidly repriming tetrodotoxin-sensitive sodium current in small spinal sensory neurons after nerve injury
25. A systematic review of antidepressants in neuropathic pain
26. Pharmacologic treatment of pain in polyneuropathy
27. Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action
28. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes
29. Size is everything: Large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects
30. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized controlled trial
31. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection
32. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study)
33. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study)
34. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials
35. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrollment study
36. Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia
37. Topical lidocaine patch relieves a variety of neuropathic pain conditions: An open-label study
38. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: A randomized, double-blind, placebo-controlled study
39. Lack of efficacy of riluzole in the treatment of peripheral neuropathic pain conditions
40. Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy
41. NK 1 (substance P) receptor antagonists: Why are they not analgesic in humans?
42. Allodynia and hyperalgesia evoked by sciatic mononeuropathy in NKI receptor knockout mice
43. St. John's wort has no effect on pain in polyneuropathy
44. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy
45. 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: A randomised, double-blind, placebo controlled trial
46. Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: A double-blind, cross-over comparison with morphine and placebo
47. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain
48. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia
49. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias
50. Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: A randomized, double-blinded, cross-over study
51. Growth factors and pain
52. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial
53. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection
54. Postherpetic neuralgia: Pathogenesis, treatment, and prevention
55. Assessment of pain in herpes zoster: Lessons learned from antiviral trials
56. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis
57. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: Prospective study with long term follow up
58. Pain and somatosensory dysfunction in acute herpes zoster
59. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia
60. Prevention of post-herpetic neuralgia: Acyclovir and prednisolone versus epidural local anesthetic and methylprednisolone
61. Intrathecal methylprednisolone for intractable postherpetic neuralgia
62. A new treatment for postherpetic neuralgia